Redeye comments on Imint’s Q1 report, which showed tenacity, and revises the sales estimates slightl...
Redeye raises its estimates following yesterday's news about the large TRaaS order from Australia.
Cell Impact uppvisade stark försäljningstillväxt under första kvartalet.
Redeye is optimistic about ATOR-1017 following new data released by Alligator Bioscience at ASCO 202...
Redeye retains its positive view of Penneo following its Q1 report.
Euroafrica Digital Ventures (”Euroafrica” eller ”Bolaget”) är ett tech-bolag inom digital media med ...
Redeye briefly comments on Fluoguide’s Q1 2022 report.
CirChem presenterade nyligen sin Q1-rapport vilken var i linje med våra estimat.
Redeye updates its estimates for Beijer Group following a review of its Q1 2022.
Börsutvecklingen präglar resultatet Concejo omsatte 64 mkr i Q1 (49 mkr) motsvarande en tillväxt om ...
Redeye comments on yesterday’s Q1 report from Annexin Pharmaceuticals, which came in as expected.
Redeye states that Strax delivered a solid quarter on topline, but margins are still weak.
First Venture Sweden (”First Venture” eller ”Bolaget”) är ett investmentbolag med fokus på snabbväxa...
År 2021 blev något av ett mellanår för Zoomability, där pandemin och komponentbrist har hämmat tillv...
Redeye thinks today's announcement of the Australian TRaaS order is of major importance.
Redeye comments on MGI's Q1'22 earnings report, which we deem as solid.
Redeye initiates coverage of Freemelt, a Swedish 3D printing company producing metal 3D printers and...
We expect focus on Medical Solutions and EMC Margin, cash conversion and leverage targets likely kep...
Polygiene är ett svenskt bolag som tillhandahåller teknologier för behandlingar av textilier och and...
Imint is a Swedish fast-growing company with several paths for continued growth.
